Kinfemichael Gedif

557 total citations · 1 hit paper
13 papers, 384 citations indexed

About

Kinfemichael Gedif is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Kinfemichael Gedif has authored 13 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Ophthalmology, 10 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Molecular Biology. Recurrent topics in Kinfemichael Gedif's work include Retinal Diseases and Treatments (12 papers), Retinal Imaging and Analysis (10 papers) and Glaucoma and retinal disorders (4 papers). Kinfemichael Gedif is often cited by papers focused on Retinal Diseases and Treatments (12 papers), Retinal Imaging and Analysis (10 papers) and Glaucoma and retinal disorders (4 papers). Kinfemichael Gedif collaborates with scholars based in United States, Switzerland and France. Kinfemichael Gedif's co-authors include Adrian Koh, Georges Weissgerber, Glenn J. Jaffe, Yuichiro Ogura, Ramin Tadayoni, Frank G. Holz, Rishi P. Singh, Ursula Schmidt‐Erfurth, Pravin U. Dugel and Andrew Chang and has published in prestigious journals such as Ophthalmology, American Journal of Ophthalmology and British Journal of Ophthalmology.

In The Last Decade

Kinfemichael Gedif

12 papers receiving 368 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HAWK and HARRIER

2020 260 citations Pravin U. Dugel, Rishi P. Singh et al. Ophthalmology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kinfemichael Gedif United States	8	368	243	50	14	13	13	384
Shamika Gune United States	12	472 1.3×	433 1.8×	72 1.4×	20 1.4×	9 0.7×	35	501
Nobuhiro Terao Japan	12	395 1.1×	280 1.2×	31 0.6×	7 0.5×	5 0.4×	26	412
Wataru Kikushima Japan	14	525 1.4×	373 1.5×	39 0.8×	5 0.4×	7 0.5×	42	551
Kanako Itagaki Japan	11	289 0.8×	216 0.9×	22 0.4×	5 0.4×	7 0.5×	26	300
Marie Thulliez United States	8	447 1.2×	358 1.5×	61 1.2×	6 0.4×	14 1.1×	9	485
Miroslav Veith Czechia	6	156 0.4×	117 0.5×	18 0.4×	3 0.2×	33 2.5×	28	186
Sean D. Adrean United States	7	180 0.5×	193 0.8×	17 0.3×	37 2.6×	7 0.5×	25	241
Kiki Probst Netherlands	7	298 0.8×	75 0.3×	33 0.7×	8 0.6×	7 0.5×	8	317
Typhaine Grenet France	8	157 0.4×	116 0.5×	28 0.6×	2 0.1×	5 0.4×	22	185
Chrystel Feller Switzerland	3	401 1.1×	316 1.3×	16 0.3×	4 0.3×	6 0.5×	5	428

Countries citing papers authored by Kinfemichael Gedif

Since Specialization

Citations

This map shows the geographic impact of Kinfemichael Gedif's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kinfemichael Gedif with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kinfemichael Gedif more than expected).

Fields of papers citing papers by Kinfemichael Gedif

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kinfemichael Gedif. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kinfemichael Gedif. The network helps show where Kinfemichael Gedif may publish in the future.

Co-authorship network of co-authors of Kinfemichael Gedif

This figure shows the co-authorship network connecting the top 25 collaborators of Kinfemichael Gedif. A scholar is included among the top collaborators of Kinfemichael Gedif based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kinfemichael Gedif. Kinfemichael Gedif is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Sadda, Srinivas R., David Sarraf, Arshad M. Khanani, et al.. (2023). Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER. British Journal of Ophthalmology. 108(6). 852–858. 7 indexed citations

Tadayoni, Ramin, Glenn J. Jaffe, Frank G. Holz, et al.. (2023). Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER. Ophthalmology and Therapy. 12(4). 2209–2216.

Poor, Stephen, Georges Weissgerber, Christopher M. Adams, et al.. (2022). A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology. 239. 180–189. 13 indexed citations

Singer, Michael, Arshad M. Khanani, Armin Wolf, et al.. (2022). Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials. Ophthalmologica. 245(4). 315–322. 1 indexed citations

Lally, David R., Anat Loewenstein, Jennifer Arnold, et al.. (2022). Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies. Eye. 37(6). 1242–1248. 7 indexed citations

Regillo, Carl D., Rishi P. Singh, Robin Hamilton, et al.. (2022). Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials. Ophthalmologica. 245(5). 403–412. 11 indexed citations

Ogura, Yuichiro, Glenn J. Jaffe, Chui Ming Gemmy Cheung, et al.. (2021). Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. British Journal of Ophthalmology. 106(7). 994–999. 37 indexed citations

Singh, Rishi P., Chirag Jhaveri, Charles C. Wykoff, et al.. (2021). Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid. Ophthalmology Retina. 6(5). 377–386. 8 indexed citations

Jhaveri, Chirag, Charles C. Wykoff, Arshad M. Khanani, et al.. (2021). Early Residual Fluid-Free Status and Long-Term BCVA Outcomes: A Treatment Agnostic, Post Hoc Analysis of Pooled HAWK and HARRIER Data. American Journal of Ophthalmology. 236. 12–19. 8 indexed citations

10.

Dugel, Pravin U., Rishi P. Singh, Adrian Koh, et al.. (2020). HAWK and HARRIER. Ophthalmology. 128(1). 89–99. 260 indexed citations breakdown →

11.

Stahl, Erin D., Dominique Brémond‐Gignac, Theresa Landry, et al.. (2017). Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma. Journal of Ocular Pharmacology and Therapeutics. 33(5). 361–365. 4 indexed citations

12.

Wilson, M. Edward, Henry O’Halloran, Deborah K. VanderVeen, et al.. (2016). Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. Eye. 30(9). 1187–1194. 25 indexed citations

13.

Glazer, Louis C., Jonathan G. Williams, Carmelina Gordon, et al.. (2016). A first in human study of Intravitreal (IVT) CLG561 in Subjects with Advanced Age-Related Macular Degeneration (AMD). 57(12). 2672–2672. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact